I help biopharma executives & investors build C-level relationships in the U.S., Europe, and Asia.
A sobering assessment of London’s AIM market from my BioCentury Inc. colleague Stephen Hansen, following the recent de-listings of three U.K. biotechs. 💬 “Anybody who lists on AIM should not be surprised that there’s low liquidity and they can’t raise secondary financing.” - Tim Haines of Abingworth 💬 ✅ Full analysis: https://lnkd.in/d5VNEEKG #biotech #capitalmarkets
The biotech sector is showing promising growth, with Biotech ETFs experiencing a notable uptick: https://bit.ly/3YzaU4E Positive market indicators and advancements in the biotech industry are driving investor interest and confidence. This surge highlights the sector's resilience and potential for future gains. We specialize in providing legal support for biotech companies, helping them navigate the complex regulatory landscape and achieve their business goals. Partner with us to ensure your biotech ventures are legally sound and poised for success: https://lnkd.in/grX8gnpu #Biotech #ETFs #MarketGrowth
https://buff.ly/3TYA3mu Arch successfully concludes a fund exceeding $3 billion, reflecting a positive shift in the biotech investment landscape. Observing further indications of revival within the sector. #BiotechInvestment #Funds
How did a top 50 European Private Equity investor navigate the complexities of the biotechnology sector? Discover how our Client Service team was able to unlock unique insights, on a time-sensitive deadline from industry leaders across the globe. Dive into the success story 👇 https://lnkd.in/dmwsnq3z Explore our unique solutions and services 👇 https://lnkd.in/dRhRKAXC #experts #insights
Senior Vice President, Corporate Communications & Investor Relations at LaVoieHealthScience
Join me at the BIO CEO & Investor Conference - one of the largest investor conferences in our industry where institutional investors, industry analysts, and senior executives are shaping the future investment landscape of biotechnology. #bioceo24
Chief Executive Officer (CEO) and Co-founder, Tinkeso Therapeutics (formerly ImmunoKite Therapeutics)
Join me at the BIO CEO & Investor Conference - one of the largest investor conferences in our industry where institutional investors, industry analysts, and senior executives are shaping the future investment landscape of biotechnology. #bioceo24
BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial market opportunities. BION’s performance has picked up in recent months, supported by an improvement in the market environment. Its managers are optimistic about the outlook as declines in interest rates, whenever they eventuate, begin to boost investor sentiment towards the sector, especially the mid- and small-cap companies that BION favours. The fund’s managers also expect ongoing progress by portfolio holdings, as several reach key milestones over the coming months. Unlike most of its peers, BION pays an attractive 5% dividend, calculated on average share price over December each year. Edison Group #biotech #Markets #Investment https://lnkd.in/d2YZV6Ym
Evergrowth BioHealthcare Capital: Outstanding Results Since Launch launched on November 15, 2023. As of April 01 2024, the fund had returned over 51.30%, surpassing the SPDR S&P 500 ETF Trust (SPY), the Nasdaq Biotechnology Index (NBI), and the Dow Jones Industrial Average (INDU) by a wide margin. To give patients hope throughout the globe, Evergrowth invests in cutting-edge preclinical, clinical and early product-stage publicly traded biotech firms. The fund is positioned to provide investors with greater returns over the long run by outperforming market benchmarks. The Evergrowth performance data highlights the following important points: Since beginning operations, the fund has returned more than 51.30%. • The SPDR S&P 500 ETF Trust, the Nasdaq Biotechnology Index, and the Dow Jones Industrial Average have all underperformed the fund. • Evergrowth BioHealthcare Capital makes investments in cutting-edge public biotech firms in pre-trial, trial and early product stages. • Disclaimer: This unaudited record is for informational purposes only. Past performance does not guarantee future results Find out if you're a good fit at Evergrowth BioHealthcare Capital #investing #finance #biotech #healthcare
Epoch 2: Biotech Poised for 2024 Recovery 👉First financing valuations 👉VC investment size and deal activity 👉Investment by indication 👉Most active biotech investors 👉Insider round prevalence 👉Avg valuations by round 👉Pharma VC impact on valuations 👉Private M&A 👉Techbio landscape 👉Techbio deal sizes 👉Techbio step-ups https://lnkd.in/dEkBy2bY
If you are attending the Biotechnology Innovation Organization's CEO & Investor Conference next month or will be around NYC during this time, feel free to reach out. Happy to chat with you and network if nothing else while I am in town. Join me at the BIO CEO & Investor Conference - one of the largest investor conferences in our industry where institutional investors, industry analysts, and senior executives are shaping the future investment landscape of biotechnology. #bioceo24
The Biotech Growth Trust in 60 seconds… Get the lowdown from Edison’s Mel Jenner on The Biotech Growth Trust, where OrbiMed's Geoffrey Hsu and Josh Golomb remain #optimistic about biotech #stocks despite recent #valuation pressures. BIOG’s focus on smaller-cap #biotech firms has been a long-term #strength, though it recently faced #challenges. The managers anticipate a #recovery, especially if US #interest rates #decline, with small-cap stocks leading the way. Read the latest report here: https://lnkd.in/ey6QA-uP #BIOG #LSE THE BIOTECH GROWTH TRUST PLC
